LUMASIRAN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lumasiran sodium and what is the scope of patent protection?
Lumasiran sodium
is the generic ingredient in one branded drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lumasiran sodium has one hundred and sixty-seven patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for LUMASIRAN SODIUM
International Patents: | 167 |
US Patents: | 14 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | LUMASIRAN SODIUM at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUMASIRAN SODIUM
Generic Entry Date for LUMASIRAN SODIUM*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for LUMASIRAN SODIUM
International Patents for LUMASIRAN SODIUM
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Morocco | 41049 | COMPOSITIONS ET MÉTHODES D'INHIBITION DE L'EXPRESSION GÉNIQUE D'HAO1 (HYDROXYACIDE OXYDASE 1 (GLYCOLATE OXYDASE)) | ⤷ Try a Trial |
Taiwan | 202342749 | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | ⤷ Try a Trial |
Luxembourg | C00218 | ⤷ Try a Trial | |
Portugal | 3581654 | ⤷ Try a Trial | |
European Patent Office | 4321177 | CONJUGUÉS GLUCIDIQUES UTILISÉS COMME AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES) | ⤷ Try a Trial |
Brazil | 112017006469 | composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase)) | ⤷ Try a Trial |
South Korea | 20240010762 | 변형 이중-가닥 RNA 제제 (- RNA MODIFIED DOUBLE-STRANDED RNA AGENTS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LUMASIRAN SODIUM
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3581654 | 38/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 (MITTEILUNG) 20201123 |
3204015 | CA 2022 00011 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN EVENTUELT I FORM AF ET SALT; REG. NO/DATE: EU/1/20/1496 20201123 |
3581654 | CA 2021 00038 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; REG. NO/DATE: EU/1/20/1496 20201123 |
3204015 | 122022000018 | Germany | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN, GEGEBENENFALLS IN FORM EINES SALZES; REGISTRATION NO/DATE: EU/1/20/1496 20201119 |
3204015 | C20220010 00364 | Estonia | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAAN;REG NO/DATE: EU/1/20/1496 23.11.2020 |
3204015 | C03204015/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: LUMASIRANUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68239 01.12.2021 |
3204015 | C202230012 | Spain | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN, OPCIONALMENTE EN FORMA DE UNA SAL; NATIONAL AUTHORISATION NUMBER: EU/1/20/1496; DATE OF AUTHORISATION: 20201119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1496; DATE OF FIRST AUTHORISATION IN EEA: 20201119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |